The clinical performance of CMTX1 is complex and often involves multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of CMTX1 requires a combination of clinical performance, imaging, laboratory testing and pathology.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Individualised development of treatment programs for treatment and management of CMTX1 typically includes multiple-dimensional management such as drug therapy, rehabilitation prevention, regular follow-up. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many neurological diseases that have been difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule according to the changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of CMTX1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.